Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period a year ago. Net earnings attributable to BMS were $1.60 billion, or $0.75 per share, compared to $1.54 billion, or $0.69 per share, last year. Adjusted EPS rose 3% to $1.99. For the […]
Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period a year ago. Net earnings attributable to BMS were $1.60 billion, or $0.75 per share, compared to $1.54 billion, or $0.69 per share, last year. Adjusted EPS rose 3% to $1.99. For the […]
Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period a year ago.
Net earnings attributable to BMS were $1.60 billion, or $0.75 per share, compared to $1.54 billion, or $0.69 per share, last year. Adjusted EPS rose 3% to $1.99.
For the full year of 2022, the company expects adjusted EPS of $7.44-7.74.
